Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

Cancer

Volumn 120, Issue 14, 2014, Pages 2164-2173

  Hong, David S ^a   Garrido Laguna, Ignacio ^a   Ekmekcioglu, Suhendan ^a   Falchook, Gerald S ^a   Naing, Aung ^a   Wheler, Jennifer J ^a   Fu, Siqing ^a   Moulder, Stacy L ^a   Piha Paul, Sarina ^a   Tsimberidou, Apostolia M ^a   Wen, Yuejin ^a   Culotta, Kirk S ^a   Anderes, Kenna ^b   Davis, Darren W ^b   Liu, Wen ^b   George, Goldy C ^a   Camacho, Luis H ^a   Percy Ivy, Susan ^c   Kurzrock, Razelle ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Apocell Molecular Profiling and Diagnostics   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angiogenesis; bevacizumab; cediranib; phase 1

Indexed keywords

BEVACIZUMAB; CEDIRANIB; NITRATE OXIDE; NITRIC ACID DERIVATIVE; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALVEOLAR SOFT PART SARCOMA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BASAL CELL CARCINOMA; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER REGRESSION; CELL COUNT; CIRCULATING TUMOR CELL; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEMOPTYSIS; HUMAN; HUMAN TISSUE; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTHYROIDISM; HYPOXIA; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SOLID TUMOR; SYNOVIAL SARCOMA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEOPLASMS; SARCOMA; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR EMBOLISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CEREBRAL HEMORRHAGE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; QUINAZOLINES; SARCOMA; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903768222     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28701     Document Type: Article

References (46)

1. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
2. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008; 68: 918-926. (Pubitemid 351206771)
3. US Food and Drug Administration. FDA Commissioner Announces Avastin Decision. Released November 18, 2011. fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm280536.htm. Accessed April 2, 2014.
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134. (Pubitemid 46089673)
5. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16-24. (Pubitemid 46630489)
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550. (Pubitemid 44917502)
7. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342. (Pubitemid 38702844)
9. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30: 3499-3506.
10. Grothey A, Van Cutsem E, Sobrero A, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381: 303-312.
11. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007; 25: 3045-3054. (Pubitemid 47218051)
12. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005; 65: 4389-4400. (Pubitemid 40775678)
13. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010; 28: 2817-2823.
14. Bozec A, Gros FX, Penault-Llorca F, et al. Vertical VEGF targeting: a combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer. 2008; 44: 1922-1930.
15. Van Buren G 2nd, Camp ER, Yang AD, et al. The role of nitric oxide in mediating tumour blood flow. Expert Opin Ther Targets. 2006; 10: 689-701. (Pubitemid 44479977)
16. Fukumura D, Kashiwagi S, Jain RK,. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006; 6: 521-534. (Pubitemid 43980541)
17. Ridnour LA, Thomas DD, Donzelli S, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal. 2006; 8: 1329-1337. (Pubitemid 44182431)
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655. (Pubitemid 13149996)
19. National Cancer Institute. 2006 Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0. Bethesda, MD: National Cancer Institute.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216. (Pubitemid 30099779)
21. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA,. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006; 119: 861-866. (Pubitemid 44051450)
22. Flores LM, Kindelberger DW, Ligon AH, et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer. 2010; 102: 1495-1502.
23. Melnikova VO, Liu W, Zhang Y, Hong DS, Davis DW,. Development of a new, highly sensitive assay for circulating tumor cell (CTC) detection based on the CellSearch® CTC profile kit enrichment and laser scanning cytometry analysis [abstract]. Presented at: AACR 101st Annual Meeting 2010; April 17-21, 2010; Washington, DC. Abstract 2687.
24. Bland JM, Altman DG,. Survival probabilities (the Kaplan-Meier method). BMJ. 1998; 317: 1572. (Pubitemid 128719735)
25. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008; 26: 3709-3714.
26. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 1432-1439.
27. Zhu X, Wu S, Dahut WL, Parikh CR,. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007; 49: 186-193. (Pubitemid 46178407)
28. Khasraw M, Holodny A, Goldlust SA, DeAngelis LM,. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Ann Oncol. 2012; 23: 458-463.
29. Langenberg MH, van Herpen CM, De Bono J, et al. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol. 2009; 27: 6152-6159.
30. Yamamoto N, Tamura T, Yamada K, et al. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009; 64: 1165-1172.
31. Mitchell CL, O'Connor JP, Roberts C, et al. A 2-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol. 2011; 68: 631-641.
32. Schulz-Utermoehl T, Spear M, Pollard CR, et al. In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology. Drug Metab Dispos. 2010; 38: 1688-1697.
33. Gardner K, Judson I, Leahy E, et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma [abstract]. J Clin Oncol. 2009; 15 (suppl): Abstract 10523.
34. Jubb AM, Harris AL,. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010; 11: 1172-1183.
35. Jayaraman P, Parikh F, Lopez-Rivera E, et al. Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol. 2012; 188: 5365-5376.
36. Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S,. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide. 2008; 19: 133-137.
37. Engels K, du Bois A, Harter P, et al. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. J Clin Pathol. 2009; 62: 448-454.
38. Eggen T, Sager G, Arnes M, Pettersen I, Orbo A,. Expression of iNOS-a favourable prognostic marker for early-stage carcinoma of the uterine cervix. Anticancer Res. 2011; 31: 2319-2325.
39. Jones MK, Tsugawa K, Tarnawski AS, Baatar D,. Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem Biophys Res Commun. 2004; 318: 520-528. (Pubitemid 38553811)
40. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG,. The role of nitric oxide in cancer. Cell Res. 2002; 12: 311-320. (Pubitemid 135708343)
41. Kilbourn RG, Gross SS, Lodato RF, et al. Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginine. J Natl Cancer Inst. 1992; 84: 1008-1016.
42. Chang CI, Liao JC, Kuo L,. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 2001; 61: 1100-1106. (Pubitemid 32174431)
43. Msaouel P, Koutsilieris M,. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer. 2011; 11: 336.
44. Danila DC, Fleisher M, Scher HI,. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 2011; 17: 3903-3912.
45. Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology. 2010; 138: 1714-1726.
46. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR,. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res. 2006; 12: 4605-4613. (Pubitemid 44297811)